Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 207

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 207
---
 |         |
| Bryan Ball                                               |     |                | 105,809 |     |                | 1.92 |     |                |  20,000 |     |                |  38,400 |
| Chief Technical Operations Officer                       |     |                |         |     |                |      |     |                |         |     |                |         |
| Neil Desai                                               |     |                |       — |     |                |      |     |                |       — |     |                |       — |
| Former Executive Chairman                                |     |                |         |     |                |      |     |                |         |     |                |         |
| Loretta Itri                                             |     |                | 136,813 |     |                | 1.92 |     |                |  30,000 |     |                |  57,600 |
| Former Chief Medical Officer                             |     |                |         |     |                |      |     |                |         |     |                |         |
| All executive officers, as a group                       |     |                | 596,653 |     |                | 1.92 |     |                | 142,000 |     |                | 272,640 |
| All directors who are not executive officers, as a group |     |                | 382,016 |     |                | 1.80 |     |                |       — |     |                |       — |
| All employees who are not executive officers, as a group |     |                | 491,406 |     |                | 1.92 |     |                |       — |     |                |       — |

| (1) | Reflects the aggregate grant date fair value of awards computed in accordance with ASC 718. |

- 143 -

Consequences if the Amended and Restated Plan Is Not Approved

If the stockholders do not approve the Equity Plan Increase, then Equity Plan Increase will not become effective and the current share limit will continue in
effect, and we will continue to make awards, subject to such share limit. However, our plans to operate our business could be adversely affected as reduced equity awards could increase employee turnover, make it more difficult to motivate and retain
existing employees and make us less competitive in hiring new talent to support our business. Additionally, as a consequence, we may need to increase the cash-based compensation incentives in hiring and retaining top talent, which could adversely